Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2.

Wang, Xiao-Xiao; Ye, Fu-Gui; Zhang, Jie; Li, Jun-Jing; Chen, Qing-Xia; Lin, Pei-Yang; Song, Chuan-Gui

Wang, Xiao-Xiao; Ye, Fu-Gui; Zhang, Jie; Li, Jun-Jing; Chen, Qing-Xia; Lin, Pei-Yang; Song, Chuan-Gui.

Afiliación

Wang XX; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.
Ye FG; Department of Breast Surgery, Key Laboratory of Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Zhang J; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.
Li JJ; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.
Chen QX; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.
Lin PY; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.
Song CG; Department of Breast Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, People's Republic of China, songchuangui@yahoo.com.

Cancer Manag Res ; 10: 4393-4400, 2018.

Article en En | MEDLINE | ID: mdl-30349372

Palabras clave

RUNX2; chemotherapeutic resistance; miR-4530; neoadjuvant chemotherapy; serum

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Manag Res Año: 2018 Tipo del documento: Article Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google